Xiaoxue Fang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaoxue Fang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Da Liu
School of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117, China
1 shared publication - Dimeng Song
School of Pharmacy, Changchun University of Chinese Medicine, Changchun, China
1 shared publication - Donglu Wu
Key Laboratory of Effective Components of Traditional Chinese Medicine, Changchun, China
1 shared publication Haoming Luo
School of Pharmacy, Changchun University of Chinese Medicine, Changchun, China
1 shared publication- Haoming Luo
College of Pharmacy, Changchun University of Chinese Medicine Changchun China
1 shared publication Jiajia Dong
College of Pharmacy, Changchun University of Chinese Medicine Changchun China
1 shared publication
Latest Publications
- 2 February 2026
- Published by Wiley in Phytotherapy Research
- Vol. 40 (4) , 1837-1861
Advances in Immune Cell Interactions and Natural Compounds Therapeutic Strategies in Alzheimer's Disease
As the global population ages, the incidence of Alzheimer's disease (AD) increases, burdening patients, families, and society. In recent years, microglia have been shown to interact with T cells, astrocytes, and other immune cells to form a complex immune microenvironment, which plays a damaging or protective role on neurons during the pathological process of AD. Herein, we review the interactions between microglia and other immune cells in the pathogenesis of AD and explore the potential of natural compounds as multi‐targeted therapeutic strategies: (1) Balancing glial cell polarization status and ameliorating neuroinflammation by inhibiting core neuroinflammatory pathways such as NF‐κB (nuclear factor kappa‐B), MAPK, and NLRP3 inflammasome; (2) modulating the gut flora‐brain axis function to inhibit central inflammation indirectly; (3) multi‐targeted interventions for core AD pathology, including amyloid‐beta (Aβ) clearance, tau phosphorylation, and synaptic plasticity. However, natural compounds still face clinical translation bottlenecks such as low bioavailability and poor blood–brain barrier permeability. Current studies have shown that nanocarrier systems and combination therapy strategies hold promise for addressing existing bottlenecks. However, systematic validation is still required for their clinical translation. This review systematically summarizes progress in the treatment of AD by regulating microglia and other immune cell interactions using natural compounds.
- 2 February 2026
- Published by Wiley in Phytotherapy Research
- Vol. 40 (4) , 1837-1861
Advances in Immune Cell Interactions and Natural Compounds Therapeutic Strategies in Alzheimer's Disease
As the global population ages, the incidence of Alzheimer's disease (AD) increases, burdening patients, families, and society. In recent years, microglia have been shown to interact with T cells, astrocytes, and other immune cells to form a complex immune microenvironment, which plays a damaging or protective role on neurons during the pathological process of AD. Herein, we review the interactions between microglia and other immune cells in the pathogenesis of AD and explore the potential of natural compounds as multi‐targeted therapeutic strategies: (1) Balancing glial cell polarization status and ameliorating neuroinflammation by inhibiting core neuroinflammatory pathways such as NF‐κB (nuclear factor kappa‐B), MAPK, and NLRP3 inflammasome; (2) modulating the gut flora‐brain axis function to inhibit central inflammation indirectly; (3) multi‐targeted interventions for core AD pathology, including amyloid‐beta (Aβ) clearance, tau phosphorylation, and synaptic plasticity. However, natural compounds still face clinical translation bottlenecks such as low bioavailability and poor blood–brain barrier permeability. Current studies have shown that nanocarrier systems and combination therapy strategies hold promise for addressing existing bottlenecks. However, systematic validation is still required for their clinical translation. This review systematically summarizes progress in the treatment of AD by regulating microglia and other immune cell interactions using natural compounds.
- Open Access
- 18 August 2023
- Published by SAGE Publications in Natural Product Communications
- Vol. 18 (8)
Cryptotanshinone, a Potential SIRT3 Inhibitor, Suppresses Colorectal Cancer Proliferation in vitro and in vivo
Cryptotanshinone (CPT) is the main pharmacologically active component of Salvia miltiorrhiza Bunge, and has been demonstrated to have inhibitory effects on a variety of cancer cell types. However, the target(s) of CPT in colorectal cancer (CRC) cells are still to be identified. The aim of this study was to investigate the molecular mechanism of CPT-induced apoptosis in CRC cells. Transcriptome sequencing revealed that 1234 genes were differentially expressed in CPT-treated SW480 cells compared with vehicle control, which were associated with signaling pathways such as PI3K/AKT, Pathways in cancer and biological processes include cell proliferation and mitochondrial function. CCK-8, colony formation assay, and CRC tumor xenograft models suggested that CPT suppressed the colony formation ability and inhibited proliferation of CRC cells in vitro and in vivo, while flow cytometry indicated that CPT arrested the cell cycle in S phase. JC-1, Hoechst and Western blot analysis indicated that CPT promoted apoptosis in CRC cells and triggered alterations in mitochondrial membrane potential. In addition, database analysis showed that high SIRT3 expression in CRC and high SIRT3 expression in CRC was associated with shorter survival times. Immunofluorescence, Western blot, and molecular docking confirmed that CPT was able to target SIRT3 and downregulate SIRT3 protein levels in a concentration-dependent manner. In summary, CPT inhibits SIRT3 protein expression and inhibits CRC proliferation in vitro and in vivo.
- 18 August 2023
- Published by SAGE Publications in Natural Product Communications
- Vol. 18 (8)
Open AccessCryptotanshinone, a Potential SIRT3 Inhibitor, Suppresses Colorectal Cancer Proliferation in vitro and in vivo
Cryptotanshinone (CPT) is the main pharmacologically active component of Salvia miltiorrhiza Bunge, and has been demonstrated to have inhibitory effects on a variety of cancer cell types. However, the target(s) of CPT in colorectal cancer (CRC) cells are still to be identified. The aim of this study was to investigate the molecular mechanism of CPT-induced apoptosis in CRC cells. Transcriptome sequencing revealed that 1234 genes were differentially expressed in CPT-treated SW480 cells compared with vehicle control, which were associated with signaling pathways such as PI3K/AKT, Pathways in cancer and biological processes include cell proliferation and mitochondrial function. CCK-8, colony formation assay, and CRC tumor xenograft models suggested that CPT suppressed the colony formation ability and inhibited proliferation of CRC cells in vitro and in vivo, while flow cytometry indicated that CPT arrested the cell cycle in S phase. JC-1, Hoechst and Western blot analysis indicated that CPT promoted apoptosis in CRC cells and triggered alterations in mitochondrial membrane potential. In addition, database analysis showed that high SIRT3 expression in CRC and high SIRT3 expression in CRC was associated with shorter survival times. Immunofluorescence, Western blot, and molecular docking confirmed that CPT was able to target SIRT3 and downregulate SIRT3 protein levels in a concentration-dependent manner. In summary, CPT inhibits SIRT3 protein expression and inhibits CRC proliferation in vitro and in vivo.